Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Influence of Fluid Intake on Mental Performance

24 de agosto de 2026 atualizado por: Liverpool John Moores University

Does Altering Daily Fluid Intake and Hydration Status Influence Cortisol Reactivity to Acute Psychosocial Stress?

Over half of the adult population in Europe, Asia and Latin America fail to meet adequate water intake guidelines as advised by the European Food Safety Authority (EFSA; 2.5 and 2 litres/day for men and women, respectively coming from both food and drinks). Increasing epidemiological evidence suggests that chronic low fluid intake may be associated with an increased risk of cardiovascular, metabolic, and renal diseases. The association between chronic low fluid intake and increased morbidity risk may be underpinned by elevations in key water-regulating hormones, such as arginine vasopressin (AVP) and its surrogate copeptin, which influence glucose regulation and renal function. For example, AVP stimulates the hypothalamic-pituitary adrenal (HPA) axis to release the stress hormone cortisol with potentially far-reaching effects on metabolism, immunity and inflammation. Prospective cohort studies have demonstrated that exaggerated cortisol responses to acute stress are associated with poor health outcomes.

A recent cross-sectional study (NCT05491122) from our group found that individuals with a low habitual fluid intake experienced greater cortisol reactivity to acute stress than those with a high habitual intake. The findings of this study may provide a potential explanation for why poor hydration and low fluid intake have negative effects on long-term health. We now aim to explore whether altering fluid intake influences cortisol reactivity to acute stress.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

192

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Liverpool, Reino Unido
        • Recrutamento
        • Liverpool John Moores University
        • Contato:
        • Contato:
        • Subinvestigador:
          • William J Searle, PhD
        • Subinvestigador:
          • Harry K Bell, MSc
        • Subinvestigador:
          • Danielle H McQueen, MSci
        • Investigador principal:
          • Neil P Walsh, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Individuals who…

    • …are free-living, who fully understand and agree to the objectives of the study, who gave, signed and dated informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
    • …are 'healthy' men and current combined oral contraceptive (COC)-using women (having taken the COC for at least 3 months and should they be eligible and willing to participate, are happy to continue taking the same COC during the duration of their participation).
    • …are aged 18-35 years
    • …engage in < 5 hours of vigorous exercise a week. This information will be obtained during the initial study brief and using the health screening questionnaire.
    • …have a habitual fluid consumption of ≤ 1.6 L/day OR ≥ 2.9 L/day for men and ≤ 1.5 L/day OR ≥ 2.5 L/day for women, verified by a 7-day fluid intake record.
    • …have a day-to-day variation in fluid intake of ≤ 25%.
    • …have a verified UOsm aligned with the following:
    • IF habitual low TFI, i.e., TFI ≤ 1.5 L/day for women OR ≤ 1.6 L/day for men have a UOsm ≥ 500 mOsm/kg.
    • IF habitual high TFI, i.e., TFI ≥ 2.5 L/day for women OR ≥ 2.9 L/day for men have a UOsm < 500 mOsm/kg.
    • …have a day-to-day variation in UOsm ≤ 28%; UOsm screening will be determined during verification and intervention periods.
    • …have access to a domestic fridge at home so that urine samples can be stored prior to laboratory visits.
    • …have a body mass index (BMI) < 30 kg/m².
    • …have an IOS or Android smart phone and therefore the ability to download the HidrateSpark mobile application.

Exclusion Criteria:

  • Individuals who…

    • …are vulnerable, as defined by individuals whose willingness to volunteer in the study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (for example, if members of a group with a hierarchical structure linked to the investigator or to the sponsor, subordinate laboratory personnel, and employees of the investigator or sponsor.
    • …are not able to answer questionnaires by writing whatever the reason.
    • …have a loss of personal liberty, by administrative or judicial decision.
    • …engage in > 5 hours of vigorous exercise a week.
    • …engage in endurance exercise bouts lasting longer than 40 minutes.
    • …do not have access to a domestic fridge at home so that urine samples can be stored prior to laboratory visits.
    • …do not have an IOS or Android smart phone and therefore do not have the ability to download the HidrateSpark application.
    • …are currently participating in another relevant clinical study (e.g., likely to influence hydration status or stress responsivity).
    • …have completed the TSST before.
    • …are expected to be living in the same home as a current participant.

Health screening

Individuals who…

  • …have had any surgery or medical procedure requiring a general anaesthesia in the preceding 4 weeks, or who plan to have one during the study.
  • …have an ongoing clinically diagnosed medical condition.
  • …are currently taking prescribed medication for an ongoing medical condition.
  • …are clinically diagnosed with one of the following psychiatric disorders known to influence stress reactivity: melancholic or atypical depression; panic disorder; obsessive-compulsive disorder; schizophrenia; social or generalised anxiety disorder; autism spectrum disorder; post-traumatic stress disorder; psychosis.
  • …have a clinically diagnosed sleeping disorder.
  • …are a current smoker (including e-cigarettes and vapes).
  • …have had a respiratory or gastrointestinal infection within the last 2 weeks.
  • …have a clinically diagnosed eating disorder.
  • …have a special medicated diet (e.g., for obesity, anorexia, metabolic pathology).
  • …have changed their dietary habits within the last 4 weeks or plan to change their diet during the study (e.g., start of a high-fibre diet, intentionally reducing or increasing calorie intake).
  • …take dietary supplements known to influence stress reactivity (e.g., high-dose caffeine).
  • …are women not currently on COC (e.g., naturally menstruating, or on progestogen-only forms of contraception, such as IUS, mini-pill, implant or injection).
  • …are women currently using COC but for < 3 months prior to reading the participant information sheet or not planning to continue taking COC during their potential participation in the study.
  • …are pregnant women or women planning to become pregnant during the study or are breast-feeding women.

Total fluid intake screening

Individuals who…

  • …have a daily total fluid intake of:
  • Men: between 1.6 and 2.9 L/day.
  • Women: between 1.5 and 2.5 L/day.
  • …have a day-to-day variation in fluid intake of >25%.
  • …have a UOsm of:
  • Men: < 500 mOsm/kg if habitual TFI is ≤ 1.6 L.day or ≥ 500 mOsm/kg if habitual TFI is ≥ 2.9 L/day.
  • Women: < 500 mOsm/kg if habitual TFI is ≤ 1.5 L/day or ≥ 500 mOsm/kg if habitual TFI is ≥ 2.5 L/day.
  • …have a day-to-day variation in UOsm > 28%.
  • …habitually consume > 1.3 L/day of caffeinated hot beverages (e.g., tea, coffee; 1.3 L equates to 4 average sized mugs) as estimated by a fluid intake record questionnaire.
  • …consume ≥ 91 units of alcohol per month (equivalent to more than 3 pints of beer per day or more than 3 large glasses of red wine per day).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Verification period
7 consecutive days where participants will drink fluids as they do normally do.
Experimental: Intervention period

7 consecutive days where the participants will be randomly assigned to either the habitual or intervention condition.

  • Habitual: maintain their usual daily total fluid intake.
  • Intervention: habitual low daily TFI will be prescribed a total fluid intake of 3.5 L/day for men and 3.3 L/day for women. Habitual high daily total fluid intake will be prescribed a total fluid intake of 1.3 L/day for both men and women.

On day 8, participants will perform a psychosocial stress test.

Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target total fluid intake.

7-day intervention where the intake of drinking water will either be maintained at habitual level, increased (if habitually low) or decreased (if habitually high). The TFI prescriptions during the intervention are derived from the mean TFI of habitually low and habitually high drinkers from a sex, age and country matched population. Specifically, habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women and habitually high drinkers will be permitted a TFI of 1.3 L/day. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Salivary cortisol reactivity to acute psychosocial stress
Prazo: Assessed during the main trial (day 8 of the intervention period). Saliva samples will be taken pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) stress test.
Changes in the concentration of salivary free cortisol throughout the psychosocial stress test. Cortisol will be measured in stimulated saliva samples and analysed by ELISA. Delta changes (increase/decrease) in cortisol response will also be calculated.
Assessed during the main trial (day 8 of the intervention period). Saliva samples will be taken pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) stress test.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Plasma copeptin
Prazo: Copeptin will be assessed using a single blood sample taken on the morning of the main trial (day 8 of intervention period).
Plasma copeptin will be analysed by ELISA and compared cross-sectionally between intervention conditions.
Copeptin will be assessed using a single blood sample taken on the morning of the main trial (day 8 of intervention period).
Urine osmolality (UOsm)
Prazo: Late-afternoon urine samples will be collected on days 6 and 7 of the verification and intervention periods. Spot urine samples will be collected on the morning and afternoon visits of the main trial (day 8 of the intervention period).
The concentration of osmotic solutes present in the urine, measured using a freezing point depression osmometer.
Late-afternoon urine samples will be collected on days 6 and 7 of the verification and intervention periods. Spot urine samples will be collected on the morning and afternoon visits of the main trial (day 8 of the intervention period).
Urine colour
Prazo: Late-afternoon urine samples will be collected on days 6 and 7 of the verification and intervention periods. Spot urine samples will be collected on the morning and afternoon visits of the main trial (day 8 of the intervention period).
Urine colour, a common marker used for assessing hydration status, will be assessed using a urine colour chart that has been developed to assess urine concentration in healthy humans.
Late-afternoon urine samples will be collected on days 6 and 7 of the verification and intervention periods. Spot urine samples will be collected on the morning and afternoon visits of the main trial (day 8 of the intervention period).
Plasma osmolality
Prazo: A venous blood sample will be taken on the morning of the main trial (day 8 of the intervention period).
A marker of intracellular osmolality, measured using a freezing point depression osmometer. Plasma will be derived from venous blood.
A venous blood sample will be taken on the morning of the main trial (day 8 of the intervention period).
Sleep duration
Prazo: Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8.
Total sleep time (minutes) will be measured using accelerometery-based movement data recorded using a wrist-worn actigraph.
Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8.
Sleep efficiency
Prazo: Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8.
Sleep efficiency will be calculated using the following equation: (total sleep time/total time in bed) * 100.
Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8.

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
State anxiety (STAI-S) response to acute psychosocial stress
Prazo: Assed during the main trial (day 8 of the intervention period). The STAI-S will be administered pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) stress test.
State anxiety will be assessed throughout the acute stress test using the state aspect (form Y1) of the State-Trait Anxiety Inventory (STAI-S).
Assed during the main trial (day 8 of the intervention period). The STAI-S will be administered pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) stress test.
Subjective stress response to acute psychosocial stress
Prazo: Assessed during the main trial (day 8 of the intervention period). The Subjective Stress Scale will be administered pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) post stress test.
Subjective stress will be assessed using the Subjective Stress Scale, a 0-9 Likert scale where participants rate how stressed they feel right now (0 = no subjective stress experience, 4 = moderate subjective stress experience, 9 = extreme subjective stress experience).
Assessed during the main trial (day 8 of the intervention period). The Subjective Stress Scale will be administered pre (-30 and -5 minutes) and post (+0, +10, +20, +30, +45 and +60 minutes) post stress test.
Trait anxiety (STAI-T) profiling
Prazo: The STAI-T will be administered once, immediately after enrolling.
Trait anxiety will be measured using the trait aspect (form Y2) of the State-Trait Anxiety Inventory (STAI-T). The STAI-T will be used as a part of participant profiling and demographic assessment.
The STAI-T will be administered once, immediately after enrolling.
Sleep quality (PSQI) profiling
Prazo: The PSQI will be administered once, immediately after enrolling.
The Pittsburgh Sleep Quality Index (PSQI) will be used to profile participants' sleep quality in the month prior to the study.
The PSQI will be administered once, immediately after enrolling.
Perceived stress (PSS) profiling
Prazo: The PSS will be administered once, immediately after enrolling.
The Perceived Stress Scale (PSS) will be used to profile participants' perceived stress in the month prior to the study.
The PSS will be administered once, immediately after enrolling.
Perceived stress during the verification and intervention periods
Prazo: The PSS-week will be administered on the familiarisation visit (between verification and intervention periods) and the morning of the main trial (day 8 of the intervention period).
A modified version of the PSS referring to the "last week" instead of "last month" (PSS-week) will be used to assess perceived stress during the verification and intervention periods.
The PSS-week will be administered on the familiarisation visit (between verification and intervention periods) and the morning of the main trial (day 8 of the intervention period).
Sleep quality during the verification and intervention periods
Prazo: Up to 2 weeks. Assessed daily from day 1-7 of the verification period and day 1-7 of the intervention period.
Participants will rate their sleep quality for the previous night on scale of 1 to 4. 1 = Very Poor, 2 = Poor, 3 = Good, 4 = Very good. This question will be completed as part of a larger daily study diary.
Up to 2 weeks. Assessed daily from day 1-7 of the verification period and day 1-7 of the intervention period.
Mood during the verification and intervention periods
Prazo: The BRUMS will be administered on the familiarisation visit (between verification and intervention periods) and morning of the main trial (day 8 of the intervention period).
The Brunel Mood Scale (BRUMS) will be used to assess mood over the last week, and will be used to characterise mood during the verification and intervention periods.
The BRUMS will be administered on the familiarisation visit (between verification and intervention periods) and morning of the main trial (day 8 of the intervention period).
Nocturia during the verification and intervention periods
Prazo: Up to 2 weeks. Assessed daily from day 1-7 of the verification period and day 1-7 of the intervention period.
The number of night time voids will be self-reported, followed by a question assessing how much this bothered the participant on a scale of 1 (Not at all) to 10 (A great deal). These will be completed as part of a larger daily study diary.
Up to 2 weeks. Assessed daily from day 1-7 of the verification period and day 1-7 of the intervention period.
Heart rate during acute psychosocial stress
Prazo: Continuously measured during the stress test on the main trial (day 8 of the intervention period). Heart rate measurement will start at 30 minutes pre-stress test and continue until 60 minutes post-stress test.
Heart rate will be measured using a telemetric chest strap.
Continuously measured during the stress test on the main trial (day 8 of the intervention period). Heart rate measurement will start at 30 minutes pre-stress test and continue until 60 minutes post-stress test.
Thirst sensation during the verification and intervention periods
Prazo: Every evening during days 1-7 of the verification and intervention periods.
A subjective rating of thirst will be recorded on a scale from 0 (not thirsty at all) to 7 (very, very thirsty) and a visual analogue scale ranging from "not thirsty" to "very thirsty". The ratings will be completed in the evening (approx. 30 min before bed) as part of a larger daily study diary.
Every evening during days 1-7 of the verification and intervention periods.
Daily total fluid intake (TFI) during the verification and intervention periods
Prazo: Up to 15 days. Daily from day 1 to 7 of the verification period and day 1 to 8 of the intervention period.
TFI will be recorded as part of a larger daily study diary. For this study, TFI refers to all drinks consumed e.g., water, tea/coffee, milk, juice, soft drinks and alcohol. Each drink will be recorded as close to the time of consumption as possible.
Up to 15 days. Daily from day 1 to 7 of the verification period and day 1 to 8 of the intervention period.
Skin issue profiling
Prazo: The SkinCARE Questionnaire will be administered once, during the familiarisation visit (between verification and intervention periods).
The SkinCARE Questionnaire will be used to profile participants for self-reported skin issues experienced in the previous 4 weeks.
The SkinCARE Questionnaire will be administered once, during the familiarisation visit (between verification and intervention periods).
Physical activity
Prazo: Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8
Actigraphy data analysed to estimate physical activity
Verification period: an actigraph will be worn continuously from day 5 until the end of the verification period. Intervention period: an actigraph will be worn continuously from day 5 until the stress test on day 8

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Investigador principal: Neil P Walsh, PhD, Liverpool John Moores University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

22 de junho de 2026

Conclusão Primária (Estimado)

1 de setembro de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

17 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de agosto de 2026

Primeira postagem (Real)

27 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de agosto de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Everyday Hydration Study 1

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Only IPD used in the results publication(s).

Prazo de Compartilhamento de IPD

Beginning 3 months after publication with no end date.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever